Publications &
Presentations
In our pursuit of scientific advancement we are committed to sharing our acquired knowledge through actively publishing our data in peer-reviewed journals and academic conferences. We aim to provide a deeper understanding through extensive study and analysis on ileal bile acid transporter (IBAT) inhibition, for both the scientific and patient communities.
Research Updates
Featured Presentations & Publications
Long-term maintenance of response and improved liver health with maralixibat in patients with progressive familial intrahepatic cholestasis (PFIC): 2-year data from the MARCH-ON study
Thompson, et al. Poster Presentation, AASLD 2023.
Improvements in pruritus with maralixibat are associated with improved quality of life for patients with progressive familial intrahepatic cholestasis: Data from the MARCH-PFIC trial
Aqul, et al. Poster Presentation, AASLD 2023.
Maralixibat leads to significant improvement in cholestatic pruritus for children with progressive familial intrahepatic cholestasis due to TJP2 or MYO5B deficiency: Data from the MARCH-PFIC trial
Miethke, et al. Poster Presentation, AASLD 2023.
Maralixibat leads to significant improvements in cholestatic pruritus for children with progressive familial intrahepatic cholestasis without a genetic diagnosis: Data from the MARCH-PFIC trial
Horslen, et al. Poster Presentation, AASLD 2023.
Efficacy, safety and tolerability of volixibat in patients with intrahepatic cholestasis of pregnancy: A case series of 4 patients
Williamson, et al. Poster Presentation, AASLD 2023.
Latest Research Updates
Filter by topic
- SELECT
- Show all
- Alagille syndrome
- Biliary atresia
- Health economics and outcomes research
- IBAT inhibition
- LIVMARLI (maralixibat)
- Patient-reported outcomes validation
- Primary biliary cholangitis
- Primary sclerosing cholangitis
- Progressive familial intrahepatic cholestasis
- Volixibat
Until a relevant regulatory agency has approved a Mirum product for a specific disease or population, any scientific presentations regarding such disease or population are not to be considered instruction on the appropriate use of Mirum products or clinical candidates.